摘要
目的:回顾性研究柔肝颗粒辅助治疗肝硬化的疗效,以扶正化瘀胶囊为对照,分析两者优势及特点,为指导临床合理用药提供参考。方法:分析2021年3月~2023年6月就诊于江苏省中医院感染科肝硬化患者的病案,分为研究组(柔肝颗粒,105例)及对照组(扶正化瘀胶囊,106例),比较两组患者治疗3个月后肝功能与肾功能的变化,及免疫细胞、肝纤维化、肝硬度及门静脉血流等指标的差异。结果:柔肝颗粒与扶正化瘀胶囊治疗3个月均能显著改善患者肝功能(P <0.05),降低肝纤维化生化指标(P<0.05);此外,柔肝颗粒还能显著降低肝硬度值(P<0.05),提高门静脉流速(P<0.05),改善肾功能(P<0.05),改善中性粒细胞淋巴细胞比值(P<0.01);而扶正化瘀胶囊能够显著改善免疫功能(P<0.05)。结论:柔肝颗粒治疗肝硬化预后良好,对并发肝肾综合征的肝硬化患者更推荐使用柔肝颗粒。
Objective:The efficacy of Rougan Granules in the treatment of liver cirrhosis was retrospectively studied,taking Fuzheng Huayu Capsules as control,to analyze its advantages and characteristics and provide reference for guiding clinical rational drug use.Methods:The medical records of 99 patients with liver cirrhosis treated in the Department of Infection of Jiangsu Provincial Hospital of Traditional Chinese Medicine during the period from March 2021 to June 2023 were analyzed.On the basis of the antiviral treatment with entecavir,the patients were divided into the study group(105 cases treated with Rougan Granules)and the control group(106 cases treated with Fuzheng Huayu Capsules).The differences of liver function,renal function,immune cells,liver fibrosis,liver hardness and portal vein blood flow between the two groups before and after treatment were compared.Results:After treatment for 3 months,both Rougan Granules and Fuzheng Huayu Capsules significantly improved the liver function of patients(P<0.05)and the biochemical indicators showed relieved liver fibrosis(P<0.05).In addition,Rougan Granules significantly reduced the hardness of liver(P<0.05),increased the flow rate of portal vein(P<0.05),improved renal function(P<0.05),and improved the ratio of neutrophil to lymphocyte(P<0.01).Fuzheng Huayu Capsules significantly improved immune function(P<0.05).Conclusion:Rougan Granules has a good prognosis in the treatment of liver cirrhosis,and it is more recommended to use Rougan Granules for patients with liver cirrhosis complicated with hepatorenal syndrome.
作者
方慧华
邢木兰
王玉兰
束雅春
陈志鹏
吴丽
FANG Huihua;XING Mulan;WANG Yulan;SHU Yachun;CHEN Zhipeng;WU Li(School of Pharmacy,Nanjing University of Chinese Medicine,Nanjing 210023,China;Department of Pharmacy,Jiangsu Province Hospital of Chinese Medicine,Nanjing 210004,China)
出处
《药学与临床研究》
2023年第6期534-538,共5页
Pharmaceutical and Clinical Research
基金
国家自然科学基金资助项目(No.81873287)
南京中医药大学自然科学基金项目(XZR2021011)。
